Pharma Equity Group A/S Stock

Pharma Equity Group A/S Debt

The Debt of Pharma Equity Group A/S (PEG.CO) as of Aug 18, 2026 is 7.14 M DKK. In the previous year, Debt was 9.50 M DKK — a change of -24.89% (lower).

Debt

7.14 MDKK

YoY

-24.89%

Last updated:

In 2026, Pharma Equity Group A/S's total debt was 7.14 M DKK, a -24.89% change from the 9.50 M DKK total debt recorded in the previous year.

Access this data via the Eulerpool API
Get Free API Key

Pharma Equity Group A/S Stock analysis

What does Pharma Equity Group A/S do? Blue Vision A/S is a company specializing in the development, production, and marketing of underwater technology. It was founded in 1992 and is headquartered in Holstebro, Denmark. The company focuses on underwater lighting, underwater inspection cameras, and underwater communication. It specializes in manufacturing underwater lighting products for the offshore industry, ports, and shipping. It also produces underwater inspection cameras for inspecting underwater structures without the need for divers. In addition, the company has developed devices for underwater communication, which are crucial in the offshore industry and military sector. Blue Vision A/S emphasizes innovation and technology, holding patents and investing in digital technology to improve inspection systems. In summary, Blue Vision A/S specializes in underwater technology and offers solutions for the offshore industry, ports, and shipping. The company is committed to innovation and technology to provide the best solutions to its customers. Pharma Equity Group A/S is one of the most popular companies on Eulerpool.

Debt Details

Understanding Pharma Equity Group A/S's Debt Structure

Pharma Equity Group A/S's total debt refers to the cumulative financial obligations the company owes to external parties. This can include short-term and long-term borrowings, bonds, loans, and other financial instruments. Assessing the company's debt levels is crucial for evaluating its financial health, risk profile, and ability to fund operations and expansions.

Year-to-Year Comparison

Analyzing Pharma Equity Group A/S's debt structure over the years provides insights into the firm’s financial strategy and stability. A reduction in debt can indicate financial strength and operational efficiency, while an increase may signal growth investments or potential financial challenges ahead.

Impact on Investments

Investors pay close attention to Pharma Equity Group A/S’s debt levels as they can influence the company’s risk and return profiles. Excessive debt can lead to financial strain, while moderate and well-managed debt can be a catalyst for growth and expansion, making it a critical aspect of investment evaluations.

Interpreting Debt Fluctuations

Shifts in Pharma Equity Group A/S’s debt levels can be attributed to various operational and strategic factors. An increase in debt might be geared towards funding expansion projects or enhancing operational capacity, while a decrease may indicate profit realizations or an approach to minimize financial risk and leverage.

Frequently Asked Questions about Pharma Equity Group A/S stock

Debt of Pharma Equity Group A/S is 7.14 M DKK in 2026.

Debt of Pharma Equity Group A/S changed from 9.50 M DKK to 7.14 M DKK, representing a -24.89% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Debt Pharma Equity Group A/S since 2006 – with annual values, charts, and detailed analysis.

Debt's DKK is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Debt's Pharma Equity Group A/S historically and in real time.

Access this data via the Eulerpool API
Get Free API Key

Balance Sheet — Pharma Equity Group A/S

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — Pharma Equity Group A/S